QCG
NEOS

Quadrant Capital Group’s Neos Therapeutics, Inc NEOS Stock Holding History

Quadrant Capital Group’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-824
Closed -$3K – 2353
2018
Q3 		$3K Hold
824
– – ﹤0.01% 1786
2018
Q2 		$5K Hold
824
– – ﹤0.01% 1590
2018
Q1 		$6K Hold
824
– – ﹤0.01% 1503
2017
Q4 		$8K Hold
824
– – ﹤0.01% 1305
2017
Q3 		$7K Hold
824
– – ﹤0.01% 1367
2017
Q2 		$6K Hold
824
– – ﹤0.01% 1312
2017
Q1 		$5K Hold
824
– – ﹤0.01% 1359
2016
Q4 		$4K Buy
+824
New +$5.58K ﹤0.01% 1338

Other funds holding NEOS

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Quadrant Capital Group's NEOS Position: Q4 2018 in Review

Quadrant Capital Group sold out of Neos Therapeutics, Inc (NEOS) in Q4 2018, closing a stake of 824 shares — an estimated $3K sold.

Quadrant Capital Group first reported a position in NEOS in Q4 2016 and held it in 8 quarters. The position peaked at $8K in Q4 2017. 63 funds tracked by Wall St. Rank hold NEOS as of Q4 2018.

  • Quadrant Capital Group reported no remaining Neos Therapeutics, Inc position as of Q4 2018 after selling out during the quarter.
  • Quadrant Capital Group sold 824 Neos Therapeutics, Inc shares in Q4 2018, an estimated $3K.
  • Quadrant Capital Group first reported a position in Neos Therapeutics, Inc in Q4 2016 and held it in 8 quarters.
  • Quadrant Capital Group's Neos Therapeutics, Inc position peaked at $8K in Q4 2017.
  • 63 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q4 2018.

Based on Quadrant Capital Group's 13F filing for Q4 2018, filed 17 Jan 2019.